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Abstract 
 
Sickness refers to a set of coordinated physiological and behavioral changes in 
response to systemic inflammation. It is characterized by fever, malaise, social 
withdrawal, fatigue, and annorexia. While these responses collectively represent a 
protective mechanism against infection and injury, increasing lines of evidence 
indicate that over-exaggerated or persistent sickness can damage the brain, and could 
possibly raise the risk to developing delirium. Therefore, a clear understanding in 
sickness will be beneficial. It has long been believed that sickness results from 
increased systemic cytokines occurring during systemic inflammation. However, in 
recent years more and more conflicting data have suggested that development of 
sickness following peripheral immune challenge could be independent of cytokines. 
Hence, it is confusing as to whether cytokines really do act as primary mediators of 
sickness, or if they are secondary to alternative inducing factor(s). In this review, we 
will (1) introduce the relationships between systemic inflammation, cytokines, 
sickness, and delirum, and (2) attempt to interpret the recent controversies.  
 
Keywords: Cytokines; Sickness; Systemic inflammation; Delirium 
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1. Introduction 
 
We all prefer to live healthily and to be free of sickness. Getting sick because of 
infection (Campisi et al., 2003; Dantzer et al., 2008; Hart, 1988) or injury (Liu et al., 
2008; Swain and Le, 1998) is discomforting and interferes greatly on our daily lives. 
While sickness was traditionally thought as a malfunction due to systemic 
inflammatory events, it is in fact an adaptive mechanism to facilitate recovery. This is 
mediated by a series highly coordinated physiological and behavioral changes, 
including fever, pain, fatigue, cognitive loss, anorexia, anhedonia, and social 
withdrawal (Dantzer, 2009; Dantzer et al., 2008; Hart, 1988), which will be 
referred to as sickness or sickness responses throughout this review. There is now 
ample evidence to show that these alterations can indeed help to fight infection (Hart, 
1988). For example, an elevation in body temperature during fever is not only 
unfavorable to the growth of some pathogens, but also stimulates the activation and 
proliferation of immune cells. A reduction of appetite leads to a lowered intake of iron, 
which is important for the growth and replication of many pathogens. Nevertheless, 
while these responses are useful if well controlled, over-exaggerated sickness can be 
damaging. For instance, a persistent increase of brain temperature during fever might 
enhance neuronal excitotoxicity (Suehiro et al., 1999) and lead to abnormalities of 
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blood-brain-barrier permeability (Sharma and Hoopes, 2003). A lowered food intake 
and greater thermogenesis would cause weight loss in a long run. Moreover, there is 
now evidence to suggest that dysregulated sickness responses, together with other risk 
factors such as aging and pre-exisiting dementia, could lead to delirium (de Rooij et 
2007; Holmes et al., 2011). Hence, it will be advantageous if we can have a detailed 
understanding on the mechanisms by which sickness develops, and to implement 
suitable approaches to maximize their benefits without causing severe side effects. 
 Given that individual symptoms of sickness are regulated by specific regions in 
the brain, and that they are natural responses to systemic inflammation, it is 
to think that there are some biological signals relating the inflammatory events 
occurring at the periphery to the brain changes required for sickness responses. Over 
the last two decades, cytokines have emerged to be these linking signals. Accordingly, 
systemic inflammation triggers drastic releases of pro-inflammatory cytokines, 
including IL-1β, IL-6, and TNF-α, all of which can act on the brain, despite the 
blood-brain barrier, and lead to sickness. A number of neural and humoural routes are 
involved. Nevertheless, an increasing number of reports have shown that under some 
occasions, sickness following peripheral immune challenge could be independent of 
central and peripheral cytokine increases (Campisi et al., 2003; Murray et al., 2011; 
Teeling et al., 2010; Teeling et al., 2007). Therefore, we question the importance of 
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cytokines, arising both systemically and within the brain, as mediators of sickness. 
the induction of cytokines alone be sufficient to cause sickness? Or are they simply 
secondary to alternative triggers of sickness?  
 Here, we summarize the relationships between systemic inflammation, cytokines, 
and sickness. Based on this background, we try to interpret the emerging controversial 
issues, and point out the gaps of knowledge. Moreover, since delirium may result 
over-exaggerated sickness (de Rooij et al., 2007; Holmes et al., 2011), we will also try 
to suggest possible roles of cytokines in delirum. 
 
2. Cytokines are induced centrally and peripherally during systemic 
inflammation 
 
 Inflammation describes a cascade of vascular changes (e.g. vasodilation and 
increased capillary permeability) and cellular changes (e.g. recruitment and activation 
of immune cells) in response to infection and tissue injury. These physiological 
responses are orchestrated by increased levels of cytokines produced mainly by 
activated immune cells at the site of inflammation. Once produced, cytokines act both 
locally in autocrine and paracrine manners, and systemically at distant organs 
2009; Kelso, 1998). For example, IFN- stimulates tissue macrophages to up-regulate 
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inducible nitric oxide synthase (iNOS) expression, leading to nitric oxide release 
(Blanchette et al., 2003). Nitric oxide in turn exerts antimicrobial (Mehta et al., 2012) 
and vasodilatory effects (Engelberger et al., 2011) in the microenvironment. 
Systemically, pro-inflammatory cytokines such as IL-1β and IL-6 produced at the 
inflammatory site are circulated to the liver, where they synergistically increase 
production of serum amyloid-A, which is involved in the complement cascade (Betts 
al., 1993). Yet, if we take a step further, we should ask an important question: How do 
immune cells sense invading pathogens and injured tissues and mount the cytokine 
responses for inflammation? 
In respect to systemic infection, this is accomplished via the interactions between 
pathogen-associated molecular patterns (PAMPs) and pathogen recognition receptors 
(PRRs) (Bianchi, 2007; Kawai and Akira, 2009; Lee and Kim, 2007). PAMPs are 
conserved molecular motifs present in pathogens but are absent in the host, and can 
be distinguished as non-self by the immune system. PRRs are membrane bound or 
secretory receptors specific for these PAMPs, and they are expressed by many 
cell types such as monocyte/macrophage, natural killer cells, neutrophils, and 
cells. Binding of a PAMP to the corresponding PRR activates classical NF-B, 
and IRF3 signaling pathways, leading to increased expression of pro-inflammatory 
cytokines such as IL-1β, TNF-α, IL-6, and interferons (Kawai and Akira, 2009). 
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several classes of PRRs have been identified, including the Toll-like receptors (TLRs) 
(Hedayat et al., 2011; Kawai and Akira, 2008), the nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs) (Saleh, 2011), the retinoic acid-inducible gene-I 
(RIG-I)-like receptors (RLRs) (Kawai and Akira, 2008; Liu and Gu, 2011), and the 
C-type lectin receptors (CLRs) (Osorio and Reis e Sousa, 2011), and they are 
summarized in Table 1. For instance, lipopolysaccharide (LPS), which is a component 
of the outer membrane of gram negative bacteria and a commonly used 
immunostimulant in experimental setting, is a ligand for TLR4 and signals via a 
dependent manner (Medvedev et al., 2007). 
Although tissue injury is often associated with a pathogenic stimulus, i.e. when 
one cuts his finger and exposes the underlying tissues to the limitless bacteria and 
viruses in the environment, injury alone can also trigger inflammation, a process 
as “sterile inflammation” (Chen and Nunez, 2010). An illustration of this is that 
after a person puts his finger on a hot stove, swelling and redness develop at the 
site. The mechanisms by which injury induces inflammation are less clear. It is 
that necrotic cells release endogenous danger signals known as alarmins, which act on 
innate immune cells to activate similar receptors (e.g. TLRs) and signaling pathways 
(e.g. NF-  pathway) to those used by PPRs/PAMPs, leading to cytokine production 
(Bianchi, 2007; Rosin and Okusa, 2011). Some examples of alarmins and their 
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receptors are listed in Table 2. Interestingly, IL-1α, a cytokine present normally as 
cytosolic or membrane bound forms, was found to be released from necrotic cell 
extracts, causing neutrophil recruitment in vivo and isolated mesothelial cells to 
produce CXCL1 and IL-6 (Eigenbrod et al., 2008).  
Systemic inflammation not only induces cytokines systemically, but also within 
the brain. A good example is that systemic LPS challenge causes the brain 
(Quan et al., 1998; Singh and Jiang, 2004) and macrophage-like cells (Buttini et al., 
1996; Eriksson et al., 2000; van Dam et al., 1992) to produce IL-1, which can diffuse 
the brain parenchyma (Vitkovic et al., 2000). Therefore, the brain can respond to 
PAMPs and alter its own cytokine profile.  
In addition to the generation of cytokines to trigger inflammation, infections and 
injuries can induce sickness. This leads us to the next step: Do cytokines also regulate 
the development of sickness? 
 
3. The discovery of cytokines as mediators of sickness  
 
Following the development of recombinant cytokines in the 1980s, it was 
observed that patients and animals given an exogenous source of cytokines often 
developed flu-like symptoms and neuropsychiatric complications. For example, in a 
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group of gastrointestinal cancer patients, intravenous injection of recombinant IL-1β 
resulted in fever, headache, rigors, nausea, and vomiting (Crown et al., 1991). 
Moreover, around 20% of patients receiving long term IFN-α therapy for viral 
displayed neuropsychiatric symptoms like depression and altered consciousness 
(Renault et al., 1987). In animals, administration of IL-1β and TNF-α lead to a wide 
range of sickness responses, including fever, suppressed feeding, social withdrawal, 
immobility, and weight loss (Bluthe et al., 2000a; Dantzer et al., 2008; Kent et al., 
Palin et al., 2008; Stefferl et al., 1996). In contrast, injection of IL-6 alone into the 
induces a partial spectrum of sickness only, i.e. fever and reduced voluntary activity, 
but it could act synergistically with a sub-threshold dose of IL-1β to trigger anorexia 
and weight loss (Harden et al., 2008). Interestingly, similar sickness responses were 
observed when animals were given either central or systemic injections of bacterial 
LPS, which is an inducer of cytokines including IL-1β, IL-6, and TNF-α in the brain 
and systemically (Bluthe et al., 1992; Henry et al., 2008; Huang et al., 2008). Taken 
together, these findings were suggestive for the idea that sickness induced by LPS 
resulted from increased systemic cytokines. However, this was not initially accepted 
because of the enormously high doses of cytokines used in the respective studies.   
 To confirm the effect of endogenous cytokines in mediating sickness, 
were done to verify whether deficiency of a single cytokine or its actions would blunt 
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sickness responses to LPS. The involvement of endogenous IL-1 is quite clear, 
both systemic (Bluthe et al., 1992) and central (Laye et al., 2000) injections of IL-1 
receptor antagonist (IL-1Ra) abrogated the suppressive effects of intraperitoneally 
injected LPS on social and/or feeding behaviors. Likewise, when compared to 
wild-type mice, IL-6 deficient mice exhibited less responsiveness to intraperitoneally 
and intracerebroventricularly injected LPS and IL-1β (Bluthe et al., 2000b), and in 
wild-type rats a pre-treatment with anti-IL-6 antibody abolished the effects of 
subcutaneously injected LPS on fever, voluntary running and food intake (Harden et 
2006). More importantly, by blocking the actions of TNF-α within the brain via an 
intracerebroventricular injection of a fragment of the TNF soluble receptor, IL-1R1 
deficient mice developed less severe sickness responses toward intraperitoneal 
injection of LPS (Bluthe et al., 2000a). This indicated that under physiological 
conditions, cytokines do not work independently, but rather functionally interact with 
each other in the form of cytokine networks to trigger different symptoms of sickness 
(Dantzer, 2009). 
 Thus, cytokines arising from inside and outside the brain modulate sickness. For 
cytokines arising systemically, they should signal back to the brain to take effects. 
However, since cytokines are hydrophilic molecules, they cannot freely pass through 
the blood-brain-barrier to enter the brain. This leads us to the next question: How do 
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systemic cytokines affect the brain in the presence of a BBB? 
 
4. Systemic cytokines act on the brain via multiple routes 
 
 There are many routes by which systemic cytokines act on the brain, and they 
be grossly classified into either being humoural dependent or neural dependent. 
Regarding the major humoural pathways, circulating cytokines can activate 
macrophage-like cells lining the circumventricular organs (CVO) (Dantzer, 2001, 
Dantzer et al., 2008; Schiltz and Sawchenko, 2002). These are brain regions that lack 
functional BBB, including the median eminence (ME), organum vasculosum of the 
laminae terminalis (OVLT), area postrema (AP), and the suprafornical organ (SFO). 
Upon activation, these macrophage-like cells locally secrete high levels of cytokines, 
which can then enter the brain by volume diffusion (Vitkovic et al., 2000). 
increasing lines of evidence indicate that certain cytokines such as IL-1 (Banks et al., 
2001; Banks et al., 1991), IL-1Ra (Gutierrez et al., 1994), TNF (Osburg et al., 2002), 
and IL-6 (Banks et al., 1994) can be selectively transported across the BBB in a 
blood-to-brain direction, mostly via saturable transport mechanisms. Circulating 
cytokines may also act on the brain vascular endothelium to trigger release of 
(An et al., 2011; Fabry et al., 1993; Thornton et al., 2010) and prostaglandin E2 
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(Cao et al., 2001; Cao et al., 1996; Konsman et al., 2004). The latter binds to neuronal 
PGE2 receptor 3 (EP3) and 4 (EP4) in the brainstem and hypothalamus, and regulates 
hypothalamic pituitary adrenal (HPA) axis activation and fever (Lazarus, 2006). 
 Evidence for the involvement of neural pathways in cytokine-mediated sickness 
was based on several major findings. To begin with, c-Fos is an immediate early gene 
and its expression has been commonly used as a marker of neuronal activation. An 
intraperitoneal injection of LPS, which potently stimulates cytokine production, leads 
to increased c-Fos immunopositive neurons at the primary (e.g. the nucleus tractus 
solitarius) and secondary projection areas (e.g. the supraoptic nucleus and 
paraventricular nucleus of the hypothalamus) of the vagus nerves (Dantzer, 2001; 
Dantzer et al., 2008). As the vagus nerve represents the major afferent pathway from 
the abdominal region to the brain, subdiaphragmatic vagotomy experiments were 
performed to see if this would reduce LPS-induced c-Fos expression. As expected, 
subdiaphragmatic vagotomy not only blocked LPS-induced brain c-Fos upregulation 
(Konsman et al., 2000; Wan et al., 1994), but also abolished LPS-induced brain IL-1 
mRNA at the hippocampus and hypothalamus (Laye et al., 1995) and the decrease in 
social behavior (Bluthe et al., 1994; Konsman et al., 2000). Similarly, 
subdiaphragmatic vagotomy reduced social withdrawal and brain IL-1β mRNA 
expression following intraperitoneal IL-1β challenge (Hansen et al., 1998). Later, it 
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was shown that an intraperitoneal LPS challenge up-regulated IL-1β 
immunoreactivity in immune cells associated with the abdominal vagus nerve 
(Goehler et al., 1999), vagus nerve sensory neurons express IL-1RI and intravenously 
injected IL-1β could stimulate vagus sensory activity (Ek et al., 1998), and that 
electrical stimulation of the vagus nerve elevated both brain IL-1β mRNA and protein 
levels and activated the HPA axis (Hosoi et al., 2000). Taken together, it would be 
reasonable to deduce that inflammation increases levels of IL-1β, which then 
stimulates the vagus nerve to fire electrical signals back to the brain. These signals in 
turn up-regulate brain IL-1β expression, and could possibly modulate specific brain 
regions that control social behavior. However, subdiaphragmatic vagotomy did not 
reverse social withdrawal when IL-1β was injected via other administrative routes 
(Bluthe et al., 1996a, b). This indicated that the vagus nerve is likely to be only 
responsible for triggering sickness responses when inflammation takes place at the 
abdominal region but not at other peripheral sites.  
The presence of both humoural dependent and neural dependent routes implies 
that the onset of sickness is regulated by several routes, and that different symptoms 
of sickness are also possibly controlled by separate routes. For example, 
subdiaphragmatic vagotomy prevented social withdrawal but not fever in response to 
LPS or IL-1β (Konsman et al., 2000). Also, it is obvious that cytokine messages can 
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be conveyed more quickly to the brain through the neural dependent routes than 
through the humoural dependent routes. As suggested by Dantzer, systemic 
inflammation may first activate the fast neural routes, which sensitizes the brain to the 
subsequent actions from the slow humoural routes (Dantzer, 2001, 2009). 
 
5. Cytokine-induced sickness: Can we extend our perspectives to look at cytokines 
in delirium? 
 
Apart from mediating sickness, cytokines may also regulate delirium. Delirium, 
also commonly referred to as acute confusional state, is characterized by inattention, 
altered consciousness, cognitive deficits, hallucinations, and disorientation (Dasgupta 
and Hillier, 2010). It is often precipitated by systemic inflammation, and it occurs 
much more frequently in aged and dementia patients than in young and non-dementia 
individuals (Murray et al., 2012). More importantly, delirium is strongly associated 
with prolonged hospitalization time and costs, greater subsequent cognitive decline, 
and increased mortality (Fong et al., 2009).  
   There is evidence to suggest that delirium may result from over-exaggerated 
sickness, and because cytokines are sickness mediators they may also participate in 
delirium (de Rooij et al., 2007; Holmes et al., 2011). Firstly, cytokines are increased 
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in delirious patients, and in particular blood IL-6 and IL-8 (de Rooij et al., 2007; van 
Munster et al., 2010; van Munster et al., 2008), CSF IL-8 (Hall et al., 2011), and 
brain IL-6 immunoreactivity (Munster et al., 2011) were found to be significantly 
higher in delirious patients than in non-delirious patients. Secondly, both sickness 
and delirium can be triggered by systemic inflammation, and they share several 
overlapping symptoms, including cognitive disturbances, decreased concentration, 
and apathy (Dasgupta and Hillier, 2010; Holmes et al., 2011). Thirdly, delirium can 
result from long-term IFN-α therapy in patients with chronic viral hepatitis (Renault 
et al., 1987), and that IL-1 suppresses cholinergic pathways (Li et al., 2000), which 
are also dysfunctional in delirium (Flacker and Lipsitz, 1999). Fourthly, while 
systemic inflammation leads to sickness in normal individuals, it frequently 
precipitates delirium in Alzheimer’s disease patients (Holmes et al., 2011). This is 
thought to be because neurodegeneration in Alzheimer’s disease causes “priming” of 
brain microglia, which would synthesize much more cytokines (e.g. IL-1β) upon 
systemic inflammatory insults (Chang et al., 2009; Cunningham et al., 2009; Field et 
al., 2010; Perry, 2010). 
  Owing to the lack of well established animal models of delirium, the possible 
links between cytokines and delirium is in fact still at its infancy. Until recently, the 
ME7 prion diseased mice have been suggested to be a suitable animal model for 
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delirium (Murray et al., 2012). At present stage, the urgent question we should ask is 
how we could extend our knowledge from cytokine-induced sickness to the 
relationships between cytokines and delirium, as summarized in Figure 1, and if this 
could provide insights on the prevention, treatment, and evaluation of recovery for 
delirium. For example, if cytokines are involved in delirium, then which cytokines 
can be biomarkers to predict whether a patient is likely to develop delirium, and 
which cytokines can be used to evaluate patients’ recovery after delirium? There is 
already a report suggesting that peak levels of blood IL-8 and IL-6 occur before and 
during delirium respectively in elderly patients with hip fractures (van Munster et al., 
2010; van Munster et al., 2008). Furthermore, low insulin-like growth factor 1 
(IGF-1) and high initial IFN-γ levels in blood are correlated with the incidence and 
recovery of delirium, respectively (Adamis et al., 2007). These studies are certainly 
in the correct direction, and we will need more cross-sectional analyses to test 
whether these cytokines are also associated with delirium under other inflammatory 
causes. On the other hand, it was found that dexamethasone could not reduce 
LPS-induced sickness despite blocking blood cytokine increases (Murray et al., 2011; 
Teeling et al., 2010), This suggests that targeting circulating cytokines levels may be 
ineffective against delirium, although data on manipulation of other key cytokines 
such as IL-8 still lacking. 
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  In the next section, we will highlight several interesting examples in which 
cytokines may appear to be disconnected to sickness development. Our purpose is 
not to against the model of cytokine-induced sickness, but rather we would like to 
stimulate our readers to not only redefine the importance of cytokines in mediating 
sickness, but also on top of that to explore the significance of cytokines in delirium. 
 
6. Cytokines: Can they explain everything in sickness? 
 
 In previous sections, we have provided multiple lines of evidence to support the 
model of cytokine-induced sickness. Firstly, systemic inflammation, either because of 
infection or tissue injury, causes heightened levels of cytokines in the brain and at the 
periphery. Secondly, both exogenously administered and endogenously produced 
cytokines are involved in the induction and resolution of sickness responses, e.g. fever, 
social withdrawal, suppressed feeding. Thirdly, systemic cytokines communicate with 
the brain through a number of fast neural and slow humoural routes to trigger 
neuronal activation, increased expression of mRNA for brain cytokines, and 
production of PGE2. What remains mostly unknown is how cytokines bring about 
sickness responses at cellular and at molecular levels within the brain, but this would 
not rule out their roles in regulating sickness. The big question we should ask is how 
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important cytokines are as mediators of sickness. 
 In order to answer this question, it would be easier if we first think about it from 
another perspective: can we get sick without the effects of cytokines? In fact, from the 
literature there are several reports suggesting that sickness may develop independently 
of cytokines (Campisi et al., 2003; Murray et al., 2011; Teeling et al., 2010; Teeling et 
al., 2007). These surprising findings have enlightened us to rethink about the current 
model of cytokine-induced sickness, and led us to share our opinions on the 
importance of cytokines in mediating sickness in this review.  
While most studies have reported that the elevations of cytokines in blood and 
the brain occur before or at the same time as the onset of sickness responses, this is 
not mandatory in all cases. For example, in one study a subcutaneous injection of 
E.coli in rats caused fever and reduced activity starting from the 4
th
 hour, before the 
increases of cytokines in the brain and plasma beginning at the 6
th
 hour, and initial 
rise of circulating endotoxins at the 18
th
 hour (Campisi et al., 2003). Hence, both 
blood-borne cytokines and endotoxins were not involved in initiating sickness in this 
study. However, there was increased local cytokine synthesis at the injection site as 
early as 2
nd
 hour. Hence, prior to spilling over to the bloodstream and to be carried to 
the brain, these cytokines could have directly activated neighboring nerve terminals of 
afferent nerves, which immediately transmitted signals back to the brain to stimulate 
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the neurons controlling fever and activity, before brain cytokines were up-regulated. 
In support of this, the vagus (Bluthe et al., 1996a, b) and the glossopharygeal nerves 
(Romeo et al., 2001) are respectively responsible for communicating inflammatory 
signals from the abdominal and oral cavities to the brain. It would be expectable that 
other afferent nerve(s) would also be involved in communicating subcutaneous 
inflammatory signals back to the brain. Furthermore, even though blood-borne 
cytokines were not required for initiating sickness, activation of the fast neural routes 
may sensitize the brain to the effects of the slow humoural routes (Dantzer, 2001, 
2009). Importantly, since fever and reduced activity persisted as long as brain and 
plasma cytokines were still elevated, cytokines were still likely to be required to 
sustain sickness responses during an infection. Therefore, it should be noted that the 
induction of circulating and brain cytokines do not necessarily have to occur before 
the onset of sickness responses, even though cytokines do mediate sickness.  
 Another striking observation is that sickness responses can be effectively 
reduced without suppressing central and/or peripheral cytokine levels. In studies 
performed by Teeling et al, pretreatment of mice with indomethacin, which is a 
non-selective COX inhibitor and inhibits prostaglandins production, abrogated the 
depressive effect of an intraperitoneal injection of a subpyrogenic dose of LPS on 
burrowing activity (Teeling et al., 2007). Likewise, in another study pretreatment of 
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mice with a selective COX-1 inhibitor piroxicram, but not a selective COX-2 inhibitor 
nimesulide, attenuated the reductions of burrowing and open-field activity in response 
to a high dose of LPS injected intraperioneally (Teeling et al., 2010). Since in both 
studies administration of COX inhibitors were able to down-regulate LPS-mediated 
sickness behaviors without causing significant differences in plasma and brain 
cytokine responses, they highlight the pivotal roles of COX in controlling sickness. 
Nevertheless, we cannot conclude that cytokines are not important mediators of 
sickness. The induction of cytokines and COX-dependent products could act together 
at the brain to achieve a full spectrum of sickness responses (Blatteis et al., 2005; 
Pecchi et al., 2006).  
 The last intriguing observation is that blocking increase of plasma cytokines or 
their systemic actions is not necessarily sufficient to suppress all symptoms of 
sickness. For instance, pretreatment with dexamethasone-21-phosphate or 
dexamethasone prevented peripheral LPS-induced hypothermia and the elevations of 
circulating cytokines, but it could not inhibit the decrements in burrowing, rearing, 
and open field activity (Murray et al., 2011; Teeling et al., 2010). Similarly, systemic 
injection of neutralizing antibodies against IL-1β, IL-6, or TNF-α before LPS 
treatment did not reverse the drop in burrowing or attenuate any increase of brain 
cytokine mRNA (Teeling et al., 2007), although in another study a pretreatment with 
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anti-IL-6 but not anti-IL-1β antisera suppressed LPS-induced fever, anorexia, and the 
reduction in voluntary wheel running (Harden et al., 2006). Hence, solely managing 
plasma cytokines would not be a good therapeutic strategy to reduce sickness, 
especially if only one cytokine is reduced because cytokines share many redundant 
effects.   
Therefore, these studies are not only supportive for cytokine-induced sickness, 
but they also highlighted several key aspects of this model that are often neglected. 
Firstly, while most studies have measured cytokines in blood and at the brain, it is 
worth mentioning that cytokines arising at the inflammatory site could already signal 
to the brain via the fast neural routes and possibly be sufficient to initiate sickness 
(Campisi et al., 2003). This former event precedes the increases of plasma and brain 
cytokines, and probably also sensitizes the brain to the effects of the latter (Dantzer, 
2001, 2009). Secondly, although cytokines do regulate sickness, they are not the only 
factor governing sickness development. Other factors such as PGE2 could alone or 
synergistically act with cytokines to elicit a full-blown sickness (Lazarus, 2006; 
Teeling et al., 2010; Teeling et al., 2007). Thirdly, drugs that primarily target at the 
plasma cytokine profile are not ideal to control sickness severity, as demonstrated in 
the example of dexamethasone or dexamethasone-21 treatment towards LPS-induced 
sickness (Murray et al., 2011; Teeling et al., 2010).  
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The model of cytokine-induced sickness has been well established. Our next step 
should characterize how important cytokines are in mediating sickness under real life 
infections and injuries. Can pathological levels of cytokines alone be sufficient to 
initiate some, if not all, symptoms of sickness? To date, numerous animal experiments 
have studied the behavior and biochemical effects of either individual exogenous 
cytokines at doses that cannot be reached by the body, or high amounts of purified 
PAMPs, e.g. LPS, which elicit many non-cytokine effects in animals. Their findings 
are certainly essential to our current understanding of cytokine-induced sickness, but 
they are not necessarily translatable to real life situations. Given that in vivo cytokines 
exert their effects at picomolar to nanomolar concentrations, and that multiple 
cytokines are simultaneously up-regulated and functionally interact to form cytokine 
networks, we suggest that our research should not just focus at the effects of mega 
doses of one single cytokine at a time, but instead should move to administering lower 
and physiologically reachable doses of multiple cytokines to see their combined 
effects. Hopefully, this will also shed light on unraveling the importance of cytokines 
in delirium. 
 
7. Conclusion 
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 Cytokine-induced sickness is not new. For over two decades, we have built 
substantial knowledge in how systemic inflammation up-regulates cytokine levels, the 
effects of cytokines on behavior and fever, and the mechanisms by which systemic 
cytokines act at the brain. What we still need to clarify is how cytokines influence the 
brain at cellular and molecular levels, and the relative importance of cytokines, as 
compared to other mediators, in sickness during real life infections and injuries. 
Moreover, delirium can be regarded as an extremity of sickness. While systemic 
inflammation causes sickness in young and non-dementia individuals, it precipitates 
delirium in the aged and dementia patients. Whether elevated cytokines during 
systemic inflammation contribute significantly to delirium is still unclear, and this 
should also be our focus in the future. 
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Figure Captions 
 
Figure 1. Summary diagram illustrating the relationships between systemic 
inflammation, cytokines, sickness, and delirium. Starting from the top, systemic 
infection and tissue injury respectively give rise to pathogen-associated molecular 
patterns (PAMPs) and alarmins, which both act on innate immune cells to trigger 
production of cytokines such as IL-1β, IL-6, TNF-α. These cytokines not only 
orchestrate local and distant inflammatory changes, but can also communicate with 
the brain via the fast neural and the slow humoural routes to induce sickness. It is 
believed that activation of the fast neural routes sensitizes the brain to the effects of 
the slow humoural routes, thereby amplifying sickness responses. Alternatively, 
infections and/or injury can generate non-cytokine mediators of sickness, including 
circulating prostaglandin E2 and LPS, which can both directly take effects in the brain 
and cause sickness. Although sickness is an adaptive response to facilitate recovery, in 
extreme cases it may manifest as delirium if uncontrolled. In young and healthy 
individuals, elevated cytokine levels by systemic inflammatory events lead to sickness. 
However, in the presence of other risk factors such as having an old age and/or 
dementia (e.g. Alzheimer’s disease, AD), the same cytokines increases could possibly 
precipitate delirium.  
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Tables 
 
 
Table 1. Pathogen recognition receptors (PRRs), their respective pathogen-associated 
molecular patterns (PAMPs) and pathogens, are summarized. Note that TLR1 and 
TLR2 form heterodimers with TLR2 and TLR6 respectively. Abbreviations: CLRs, 
C-type lectin receptors; MDA5, melanoma-differentiation-associated gene 5; NALP1 
& 3, NACHT, LRR and PYD domains-containing protein 1 & 3; NLRs, NOD-like 
receptors; NOD1 & 2, nucleotide-binding oligomerization domain-containing protein 
1 & 2; RIG-I, retinoic-acid-inducible protein I; RLRs, RIG-I-like receptors; TLRs, 
toll-like receptors 
 PRR(s) PAMP Pathogen  
TLRs TLR1-TLR2 Diacyl-lipopeptides Bacteria 
TLR2-TLR6 Zymosan Fungi 
TLR2 Peptidoglycan Bacteria 
TLR3 dsRNA Viruses 
TLR4 Lipopolysaccharide Bacteria 
TLR5 Flagellin Bacteria 
TLR7 ssRNA Viruses 
TLR8 ssRNA Viruses 
TLR9 Unmethylated CpG DNA Bacteria 
NLRs NOD1 g-D-glutamyl-meso-diaminopimelic acid Bacteria 
NOD2 Muramyl dipeptide  Bacteria 
NALP1 Anthrax toxin Bacteria 
NALP3 Muramyl dipeptide Bacteria 
RLRs RIG-I 5’-PPP ssRNA, short ssRNA Viruses 
MDAP5 dsRNA Viruses 
CLRs Dectin-I β-Glucan  Fungus 
Mannose receptor Mannose-capped lipoarabinomannan Bacteria 
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Alarmin Putative receptor(s) 
High mobility group box 1 TLR2, TLR4, TLR9 
S100 proteins TLR4 
Heat shock proteins TLR2, TLR4 
Uric acid TLR2, TLR4, NALP3 
β-amyloid NALP3 
Cathelicidins TLR7, TLR9 
Defensins TLR4 
IL-1α IL-1R 
IL-33 IL-1R 
 
Table 2. Examples of alarmins and their putative receptors. Abbreviations: HMGB1, 
High mobility group box 1; NALP3, NACHT, LRR and PYD domains-containing 
protein 3; TLR, toll-like receptor 
 
Non-cytokine mediators:  
•Prostaglandins 
•LPS 
 
 
 
 
      Systemic cytokines  
 (e.g. IL-1β, IL-6, TNF-α)  
Systemic infection                                                                                            Tissue injury 
PAMPs (e.g. LPS, dsRNA)                                                                              Alarmins (e.g. HSPs, IL-1α)   
Fast neural routes Slow humoural routes 
Sickness: 
•Fever 
•Annorexia 
•Anhedonia 
 
Delirium: 
•Inattention 
•Hallucinations 
•Disorientation 
Other risk factors? 
•Aging 
•Dementia (e.g. AD) 
 
 
 
Systemic inflammation:   
•Vasodilation 
•Leukocyte infiltration 
•Acute phase response 
+ 
+ 
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